A Prospective Sub-Study of the Global Hypophosphatasia Registry

Recruiting now

Conditions studied: Hypophosphatasia

In brief

In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.

Key facts

Study ID

NCT05234567

Run by

Alexion Pharmaceuticals, Inc.

People needed

30

Starts

2022-08-25

Expected to finish

2028-07-18

Last updated by the study team

2026-02-09

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any age or sex with a confirmed diagnosis of pediatric-onset HPP (that is, first HPP sign or symptom presented at < 18 years of age).
• Currently receiving asfotase alfa treatment at Enrollment (not treatment-naïve) or the Physician has decided to resume (not treatment-naïve) or start (treatment-naïve) the participant's asfotase alfa treatment within 6 months after Enrollment.
• Participant must have documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, and a documented ALPL gene mutation (Note: An exception is made for infants with clinical features of HPP plus low ALP who need to start asfotase alfa treatment right away, at the Physician's discretion, but do not yet have a genetic result. In this case, ALPL gene documentation is not required at the time of sub-study enrollment but should be documented within 6 months after Enrollment).
• Participant or participant's parent/legally authorized representative is able to read and/or understand the informed consent and study questionnaires in the local language.
• Participant or participant's parent/legally authorized representative must be willing and able to give signed informed consent for this sub-study, and the participant must be willing to give written informed assent, if appropriate and required by local regulations.

You may not qualify if…

• Currently participating in an Alexion-sponsored interventional clinical study. Participants who have concluded participation in an Alexion-sponsored asfotase alfa clinical study are eligible to enroll in this sub-study.

Where it is running

• Clinical Trial Site — Madison, Wisconsin, United States (enrolling)
• Clinical Trial Site — Chicago, Illinois, United States (enrolling)
• Clinical Trial Site — Boston, Massachusetts, United States (enrolling)
• Clinical Trial Site — Kansas City, Missouri, United States (enrolling)
• Clinical Trial Site — Mineola, New York, United States (enrolling)
• Clinical Trial Site — Charlottesville, Virginia, United States (enrolling)
• Clinical Trial Site — Hartford, Connecticut, United States (enrolling)
• Clinical Trial Site — Columbus, Ohio, United States (enrolling)
• Clinical Trial Site — Nashville, Tennessee, United States (enrolling)
• Clinical Trial Site — Salt Lake City, Utah, United States (enrolling)
• Clinical Trial Site — Cincinnati, Ohio, United States
• Clinical Trial Site — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.